EN PL

News

EMA: Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use.

21.06.2012
This guideline addresses issues relating to the unwanted immunogenicity of monoclonal antibodies (mAbs) intended for clinical use. These include factors impacting on immunogenicity of mAbs, ...

EMA: Concept paper on the need of the guideline on clinical investigation of medicinal products for the treatment of gout

21.06.2012
At present no Committee for Medicinal Products for Human Use (CHMP) guideline has been developed for the clinical development of medicinal products aiming at prevention and / or treatment of gout ...

EMA: Questions and answers on the suspension of the marketing authorisations for oral meprobamate-containing medicines

14.06.2012
The European Medicines Agency has completed a review of the safety and effectiveness of oral meprobamate-containing medicines, due to serious side effects seen with the medicine. The Agency’s ...

EMA: Concept paper on the revision of the CHMP points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome

14.06.2012
The proposed guideline will replace \'points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome CPMP/EWP/785/97\'. Irritable bowel syndrome (IBS) is ...

EMA: Concept paper on the need for revision of the note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function

14.06.2012
The note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function (CHMP/EWP/225/02) provides recommendations on when to conduct ...

EMA: Draft guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery

06.06.2012
This guideline is a revision of the CHMP Guideline on clinical investigation of medicinal products for Prophylaxis of Intra- and Post-operative Venous Thromboembolic Risk (CPMP/EWP/707/98 Rev.1 ...

EMA: Guideline on quality of biological active substances produced by transgene expression in animals

06.06.2012
This guideline provides guidance on the approaches that should be employed in order to achieve satisfactory quality for biological drug substances proposed to be produced using transgenic animal ...

EMA: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

06.06.2012
This guideline lays down the quality requirements for a biological medicinal product claiming to be similar to another one already marketed. It addresses the requirements regarding manufacturing ...

GMP: New IMPD Guideline on the Requirements for Quality Documentation concerning Biological Investigational Medicinal Products in Clinical Trials

06.06.2012
The application to carry out a clinical trial (Investigational Medicinal Product Dossier, IMPD) is a document which must contain all the relevant quality information regarding the manufacture, ...

EMA: Guidance on centrally authorised products requiring a notification of a change for update of annexes

31.05.2012
On 23 July 2010 and after a consultation phase, the EMA communicated to all Parallel Distributors that it is not required to inform the EMA on changes to the labelling or leaflet related to any ...